MEK1 is associated with carboplatin resistance and is a prognostic biomarker in epithelial ovarian cancer

BACKGROUND: Primary systemic treatment for ovarian cancer is surgery, followed by platinum based chemotherapy. Platinum resistant cancers progress/recur in approximately 25% of cases within six months. We aimed to identify clinically useful biomarkers of platinum resistance. METHODS: A database of o...

Descripción completa

Detalles Bibliográficos
Autores principales: Pénzváltó, Zsófia, Lánczky, András, Lénárt, Julianna, Meggyesházi, Nóra, Krenács, Tibor, Szoboszlai, Norbert, Denkert, Carsten, Pete, Imre, Győrffy, Balázs
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2014
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4247127/
https://www.ncbi.nlm.nih.gov/pubmed/25408231
http://dx.doi.org/10.1186/1471-2407-14-837

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4247127/
https://www.ncbi.nlm.nih.gov/pubmed/25408231
http://dx.doi.org/10.1186/1471-2407-14-837

Ejemplares similares